[go: up one dir, main page]

EA201270528A1 - Композиции цитокинов семейства il-17 и их применение - Google Patents

Композиции цитокинов семейства il-17 и их применение

Info

Publication number
EA201270528A1
EA201270528A1 EA201270528A EA201270528A EA201270528A1 EA 201270528 A1 EA201270528 A1 EA 201270528A1 EA 201270528 A EA201270528 A EA 201270528A EA 201270528 A EA201270528 A EA 201270528A EA 201270528 A1 EA201270528 A1 EA 201270528A1
Authority
EA
Eurasian Patent Office
Prior art keywords
families
cytokines
compositions
application
molecules
Prior art date
Application number
EA201270528A
Other languages
English (en)
Inventor
Кристофер К. Гарсия
Сашанк Редди
Грегори Джеймс Сечкевич
Лорен К. Эли
Томас М. Барнс
Майкл М. Шмидт
Бракен М. Кинг
Original Assignee
Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити
Илэвэн Байотерапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити, Илэвэн Байотерапьютикс, Инк. filed Critical Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити
Publication of EA201270528A1 publication Critical patent/EA201270528A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В изобретении предложены связывающие белки, в том числе не встречающиеся в природе и модифицированные рекомбинатные белки, которые связываются с IL-17R, в том числе белки, содержащие мутантную последовательность цитокина IL-17, способы получения таких молекул и способы применения таких молекул в качестве терапевтических, профилактических и диагностических агентов.
EA201270528A 2009-10-10 2010-10-11 Композиции цитокинов семейства il-17 и их применение EA201270528A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27877909P 2009-10-10 2009-10-10
PCT/US2010/052194 WO2011044563A2 (en) 2009-10-10 2010-10-11 Il-17 family cytokine compositions and uses

Publications (1)

Publication Number Publication Date
EA201270528A1 true EA201270528A1 (ru) 2012-12-28

Family

ID=43857433

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270528A EA201270528A1 (ru) 2009-10-10 2010-10-11 Композиции цитокинов семейства il-17 и их применение

Country Status (11)

Country Link
US (1) US20130064788A1 (ru)
EP (1) EP2485763A4 (ru)
JP (1) JP2013507132A (ru)
KR (1) KR20120093932A (ru)
CN (1) CN102648002A (ru)
AU (1) AU2010303166A1 (ru)
BR (1) BR112012008444A2 (ru)
CA (1) CA2777222A1 (ru)
EA (1) EA201270528A1 (ru)
IL (1) IL219209A0 (ru)
WO (1) WO2011044563A2 (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
RU2607374C2 (ru) 2009-10-30 2017-01-10 Новозаймс Байофарма Дк А/С Варианты альбумина
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
CN103221422B (zh) 2010-07-29 2017-03-29 十一生物治疗股份有限公司 嵌合il‑1受体i型激动剂和拮抗剂
WO2012138977A1 (en) * 2011-04-06 2012-10-11 Board Of Trustees Of The Leland Stanford Junior University Structural based design of il-17 dominant negative mutants
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CA2852145C (en) 2011-10-19 2021-01-12 Morphosys Ag Antagonists of il17c for the treatment of inflammatory disorders
EP2768946A1 (en) * 2011-10-21 2014-08-27 Baylor College Of Medicine Method to measure inflammation in the conjunctiva of patients with tear dysfunction
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
PL2825556T3 (pl) 2012-03-16 2018-10-31 Albumedix A/S Warianty albuminy
JP2013253842A (ja) * 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
WO2013186236A1 (en) * 2012-06-12 2013-12-19 Orega Biotech Antagonists of il-17 isoforms and their uses
EP3417878A1 (en) * 2012-06-12 2018-12-26 Orega Biotech Antagonists of il-17 isoforms and their uses
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
SG11201507447PA (en) 2013-03-13 2015-10-29 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery
EP3741385A1 (en) * 2013-04-17 2020-11-25 Genzyme Corporation Compositions for use in a method of treating and preventing macular degeneration
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
WO2017164409A1 (ja) * 2016-03-25 2017-09-28 国立大学法人大阪大学 疾患の要因となる生体内タンパク質を標的とするコンジュゲートワクチン
EP3445352A4 (en) * 2016-04-19 2019-12-11 Azura Opthalmics Ltd. COMPOSITIONS FOR THE TREATMENT OF HYPERKERATOSIS DISEASES
WO2019018652A1 (en) * 2017-07-21 2019-01-24 The Cleveland Clinic Foundation SBE APTAMERS FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH IL-17A
EP3794024B1 (en) 2018-05-14 2023-05-10 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
EP3794022A1 (en) 2018-05-14 2021-03-24 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
JP2022527345A (ja) 2019-04-03 2022-06-01 オレガ・バイオテック Ｐｄ１阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法
MX2021013766A (es) 2019-05-14 2022-02-21 Werewolf Therapeutics Inc Restos de separacion y metodos de uso de los mismos.
US20220281967A1 (en) * 2019-08-02 2022-09-08 Orega Biotech Novel il-17b antibodies
KR102265435B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도
CN115175926A (zh) 2019-11-14 2022-10-11 狼人治疗公司 可激活细胞因子多肽及其使用方法
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
JP2023514957A (ja) 2020-02-28 2023-04-12 オレガ・バイオテック Ｃｔｌａ４阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法
WO2022032592A1 (en) * 2020-08-13 2022-02-17 Tsinghua University Interleukin-17d and cd93 as a new cytokine-receptor pair in the immune system
CN113403259B (zh) * 2021-06-04 2023-01-17 华南农业大学 一种提高克隆胚胎发育质量的添加剂及其应用
CN113563453A (zh) * 2021-07-23 2021-10-29 四川大学 鸡白细胞介素17b重组乳酸菌免疫制剂的制备和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP4373495B2 (ja) * 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
US6569419B2 (en) * 2000-02-29 2003-05-27 Zymogenetics, Inc. Methods for promoting production of myelin by Schwann cells
US20030203451A1 (en) * 2000-08-24 2003-10-30 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
DE60125563T2 (de) * 2000-10-13 2007-10-04 Eli Lilly And Co., Indianapolis Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
US7709461B2 (en) 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
MXPA03003407A (es) * 2000-10-18 2004-05-04 Immunex Corp Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.
US20040115191A1 (en) * 2002-01-24 2004-06-17 Moore Emma E Method for treating psoriasis
US20040234500A1 (en) * 2001-03-26 2004-11-25 Moore Emma E. Method for inducing proliferation of retinal stem cells
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
PL1641822T3 (pl) * 2003-07-08 2013-10-31 Genentech Inc Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
AU2007235212A1 (en) * 2006-02-10 2007-10-18 Zymogenetics, Inc. Truncated IL-17RA soluble receptor and methods of using in inflammation
US20070218065A1 (en) * 2006-03-10 2007-09-20 Jaspers Stephen R Antibodies that bind both il-17a and il-17f and methods of using the same
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
BRPI0715917A2 (pt) * 2006-08-11 2014-11-25 Schering Corp Anticorpos para il-17a
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2008118930A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
EP2144928A2 (en) * 2007-04-20 2010-01-20 Amgen Inc. Jacquelinidentification and method for using the pre-ligand assembly domain of the il-17 receptor
WO2008133684A1 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
JP2010534664A (ja) * 2007-07-23 2010-11-11 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｉｌ−１７拮抗薬を用いた線維症関連疾患治療の方法及び組成物

Also Published As

Publication number Publication date
JP2013507132A (ja) 2013-03-04
EP2485763A4 (en) 2013-10-30
CN102648002A (zh) 2012-08-22
CA2777222A1 (en) 2011-04-14
EP2485763A2 (en) 2012-08-15
WO2011044563A3 (en) 2011-06-03
US20130064788A1 (en) 2013-03-14
KR20120093932A (ko) 2012-08-23
IL219209A0 (en) 2012-06-28
AU2010303166A1 (en) 2012-05-24
WO2011044563A2 (en) 2011-04-14
BR112012008444A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
EA201270528A1 (ru) Композиции цитокинов семейства il-17 и их применение
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
MX337590B (es) Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias.
EA201370018A1 (ru) Составы рифаксимина и их применение
UA112416C2 (uk) Антитіло до fap і способи його застосування
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
PH12013500355A1 (en) Engineered anti-tslp antibody
UA105290C2 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
PH12012500843A1 (en) Engineered anti-tslp antibody
MX2021001494A (es) Anticuerpos dkk1 y metodos de uso.
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
MA34004B1 (fr) Protéines de liaison à cd127
PH12013502205A1 (en) Antibodies to il-6 and their uses
MX2010008688A (es) Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
MX2011011768A (es) Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos.
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы